Therapeutic flag
Salicylic Acid
CAS 69-72-7
Salicylic Acid (CAS 69-72-7) is a Phase 3 pharmaceutical compound with 15 bioactivity targets and 2,019 adverse event associations.
SOURCE
NLM DailyMed
Label records
3
SOURCE
EMBL-EBI ChEMBL
Bioactivity
21
SOURCE
DrugCentral
Adverse signals
2,019
SOURCE
IUPHAR/BPS
PubMed IDs
1
SOURCE
EMBL-EBI ChEMBL
B25820EEF0F0
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Primary Name
Salicylic Acid
CAS Number
69-72-7
UNII
O414PZ4LPZ
InChIKey
YGSDEFSMJLZEOE-UHFFFAOYSA-N
ChEMBL ID
CHEMBL424
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
Synonyms and normalized names
METHYL SALICYLATEKeralytDuoplantFreezoneStri-Dex
natural producttherapeutic flag
SOURCE
EMBL-EBI ChEMBL
B25820EEF0F0
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Phase 3
Late-stage clinical development phase from the compound identifier source.
ChEMBL CHEMBL424 | Small molecule
SOURCE
NLM DailyMed
5 label rows
Drug Label Active Ingredients
Active ingredient and active moiety rows from source drug product labels.
| Product | Ingredient | Active Moiety | Effective |
|---|---|---|---|
| AOAO Acne Buster Salicylic Acid Drying Serum | SALICYLIC ACID O414PZ4LPZ |
SALICYLIC ACID | 20260506 |
| Antispetic | METHYL SALICYLATE LAV5U5022Y |
SALICYLIC ACID | 20260505 |
| Follence Medicated | SALICYLIC ACID O414PZ4LPZ |
SALICYLIC ACID | 20260505 |
| New Terocin | METHYL SALICYLATE LAV5U5022Y |
SALICYLIC ACID | 20260505 |
| PEGO Acne Buster Salicylic Acid Drying Serum | SALICYLIC ACID O414PZ4LPZ |
SALICYLIC ACID | 20260505 |
SOURCE
EMBL-EBI ChEMBL
21 bioactivity rows
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Ki | 27119.587 nM | 19 | - |
| - | Potency | 34763.24545454545 nM | 9 | - |
| - | IC50 | 62015.262 nM | 9 | - |
| - | MIC | 5000000 nM | 4 | - |
| - | Kd | 1000 nM | 2 | - |
| - | MIC | 216.5 ug.mL-1 | 2 | - |
| Carbonic anhydrase 2 Enzyme |
Ki | 5.15 | - | Homo sapiens |
| Carbonic anhydrase 1 Enzyme |
Ki | 5 | - | Homo sapiens |
| Carbonic anhydrase 4 Enzyme |
Ki | 4.95 | - | Homo sapiens |
| Salicylic acid-binding protein 2 Enzyme |
- | - | - | Nicotiana tabacum |
| Carbonic anhydrase 9 Enzyme |
Ki | 4.1 | - | Homo sapiens |
| Carbonic anhydrase 12 Enzyme |
Ki | 5.06 | - | Homo sapiens |
| Carbonic anhydrase 7 Enzyme |
Ki | 4.09 | - | Homo sapiens |
| Carbonic anhydrase 6 Enzyme |
Ki | 4.92 | - | Homo sapiens |
| Carbonic anhydrase 14 Enzyme |
Ki | 4.3 | - | Homo sapiens |
| Carbonic anhydrase 13 Enzyme |
Ki | 4.17 | - | Mus musculus |
| Polyphenol oxidase 2 Enzyme |
IC50 | 4 | - | Agaricus bisporus |
| Carbonic anhydrase 15 Enzyme |
Ki | 5.14 | - | Mus musculus |
| Solute carrier family 22 member 20 Transporter |
Ki | 4.36 | - | Mus musculus |
| High mobility group protein B1 Nuclear other |
Kd | 6 | - | Homo sapiens |
| Nicotinate phosphoribosyltransferase Enzyme |
Ki | 9.8 | - | Homo sapiens |
SOURCE
DrugCentral
80 associations
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Macular degeneration | 258 | 814.105 | 10025409 |
| Completed suicide | 404 | 629.203 | 10010144 |
| Chronic sinusitis | 90 | 240.99 | 10009137 |
| Toxicity to various agents | 300 | 219.844 | 10070863 |
| Paraesthesia oral | 91 | 210.067 | 10057372 |
| Procedural pain | 91 | 201.398 | 10064882 |
| Skin burning sensation | 68 | 159.355 | 10054786 |
| Erythema | 187 | 149.787 | 10015150 |
| Vaginal flatulence | 39 | 130.907 | 10064227 |
| Therapeutic product effect incomplete | 133 | 108.737 | 10082200 |
| Female genital tract fistula | 40 | 104.693 | 10061149 |
| Dry skin | 87 | 95.01 | 10013786 |
| Vaginal discharge | 39 | 93.949 | 10046901 |
| Proctitis | 38 | 93.864 | 10036774 |
| Skin irritation | 45 | 92.929 | 10040880 |
| Skin exfoliation | 76 | 89.504 | 10040844 |
| Radiculopathy | 40 | 88.774 | 10037779 |
| Dyspepsia | 100 | 80.396 | 10013946 |
| Broncholithiasis | 15 | 76.569 | 10065037 |
| Anal inflammation | 21 | 73.154 | 10050247 |
| Lymph node calcification | 15 | 64.92 | 10056284 |
| Choroiditis | 18 | 62.856 | 10008792 |
| SARS-CoV-2 test negative | 18 | 61.683 | 10084273 |
| Frequent bowel movements | 46 | 59.023 | 10017367 |
| Exposure via ingestion | 23 | 58.273 | 10073302 |
| Drug ineffective | 401 | 58.052 | 10013709 |
| Suspected suicide | 30 | 56.914 | 10082458 |
| Oral candidiasis | 44 | 56.753 | 10030963 |
| Colitis ulcerative | 48 | 55.994 | 10009900 |
| Pain of skin | 33 | 53.812 | 10033474 |
| Lichen nitidus | 8 | 42.633 | 10024428 |
| Accident | 23 | 39.524 | 10000369 |
| Bronchial wall thickening | 15 | 38.16 | 10067182 |
| Proctalgia | 23 | 37.969 | 10036772 |
| Endophthalmitis | 20 | 36.949 | 10014801 |
| Drug hypersensitivity | 134 | 35.858 | 10013700 |
| Lower respiratory tract infection viral | 11 | 33.261 | 10065188 |
| Chemical burn of skin | 7 | 32.565 | 10057941 |
| Malaise | 171 | 31.602 | 10025482 |
| Rectal haemorrhage | 50 | 31.136 | 10038063 |
| Pyrexia | 210 | 31.004 | 10037660 |
| Weight decreased | 139 | 30.248 | 10047895 |
| Psoriasis | 59 | 29.955 | 10037153 |
| Palmar-plantar erythrodysaesthesia syndrome | 33 | 29.074 | 10033553 |
| Appendicolith | 17 | 28.688 | 10074458 |
| Soft tissue necrosis | 9 | 27.081 | 10065769 |
| Chondritis | 6 | 25.892 | 10008685 |
| Intraocular pressure increased | 18 | 25.649 | 10022806 |
| Skin swelling | 13 | 25.459 | 10053262 |
| Colitis | 44 | 23.92 | 10009887 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
SOURCE
IUPHAR/BPS
1 interaction
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| ASIC3 ASIC3 |
Channel blocker | 3.5999999046325684 pIC50 | 11588175 |
SOURCE
NLM RxNorm
9 name rows
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| SALICYLIC ACID | 9525 | SU | MTHSPL |
| Salicylic Acid | 9525 | SU | MTHSPL |
| salicylic acid | 9525 | SU | MTHSPL |
| Salicylic acid | 9525 | SU | MTHSPL |
| salicylic acid | 9525 | IN | RXNORM |
| Keralyt | 28166 | BN | RXNORM |
| Duoplant | 92540 | BN | RXNORM |
| Freezone | 217209 | BN | RXNORM |
| Stri-Dex | 220049 | BN | RXNORM |
SOURCE
SIDER
79 side-effect rows
Side Effects
SIDER side-effect terms mapped to the drug or same-CAS compound identity.
| Side Effect | Drug Name | MedDRA Type | Concept ID |
|---|---|---|---|
| Abdominal discomfort | salicylate | PT | C0232487 |
| Abdominal pain upper | salicylate | PT | C0232492 |
| Anorexia | salicylate | LLT | C0003123 |
| Asthma | salicylate | LLT | C0004096 |
| Asthma | salicylate | PT | C0004096 |
| Burning sensation | salicylate | LLT | C0085624 |
| Burning sensation | salicylate | PT | C0085624 |
| Confusional state | salicylate | LLT | C0009676 |
| Confusional state | salicylate | PT | C0009676 |
| Constipation | salicylate | LLT | C0009806 |
| Constipation | salicylate | PT | C0009806 |
| Deafness | salicylate | PT | C0011053 |
| Decreased appetite | salicylate | PT | C0232462 |
| Dermatitis | salicylate | PT | C0011603 |
| Diarrhoea | salicylate | LLT | C0011991 |
| Diarrhoea | salicylate | PT | C0011991 |
| Dizziness | salicylate | LLT | C0012833 |
| Dizziness | salicylate | PT | C0012833 |
| Dizziness | salicylate | PT | C0012833 |
| Drowsiness | salicylate | LLT | C0013144 |
| Duodenal ulcer | salicylate | LLT | C0013295 |
| Duodenal ulcer | salicylate | PT | C0013295 |
| Dysgeusia | salicylate | LLT | C0013378 |
| Dysgeusia | salicylate | PT | C0013378 |
| Dyspepsia | salicylate | LLT | C0013395 |
| Dyspepsia | salicylate | PT | C0013395 |
| Dyspepsia | salicylate | PT | C0013395 |
| Ecchymosis | salicylate | LLT | C0013491 |
| Ecchymosis | salicylate | PT | C0013491 |
| Epigastric pain | salicylate | LLT | C0232493 |
| Epistaxis | salicylate | LLT | C0014591 |
| Epistaxis | salicylate | PT | C0014591 |
| Erythema | salicylate | LLT | C0041834 |
| Erythema | salicylate | PT | C0041834 |
| Erythema multiforme | salicylate | LLT | C0014742 |
| Erythema multiforme | salicylate | PT | C0014742 |
| Faecal occult blood positive | salicylate | LLT | C0266813 |
| Feeling abnormal | salicylate | PT | C1443060 |
| Gastric ulcer | salicylate | LLT | C0038358 |
| Gastric ulcer | salicylate | PT | C0038358 |
| Hallucination | salicylate | LLT | C0018524 |
| Hallucination | salicylate | PT | C0018524 |
| Headache | salicylate | LLT | C0018681 |
| Headache | salicylate | PT | C0018681 |
| Hearing impaired | salicylate | LLT | C1384666 |
| Hearing impaired | salicylate | PT | C1384666 |
| Heartburn | salicylate | LLT | C0018834 |
| Hepatitis | salicylate | LLT | C0019158 |
| Hepatitis | salicylate | PT | C0019158 |
| Lethargy | salicylate | LLT | C0023380 |
| Lethargy | salicylate | PT | C0023380 |
| Lightheadedness | salicylate | LLT | C0220870 |
| Localized exfoliation | salicylate | LLT | C0520893 |
| Nausea | salicylate | LLT | C0027497 |
| Nausea | salicylate | PT | C0027497 |
| Occult blood positive | salicylate | PT | C0877047 |
| Oedema | salicylate | LLT | C0013604 |
| Oedema | salicylate | PT | C0013604 |
| Oesophagitis | salicylate | LLT | C0014868 |
| Oesophagitis | salicylate | PT | C0014868 |
| Pain | salicylate | PT | C0030193 |
| Pruritus | salicylate | LLT | C0033774 |
| Pruritus | salicylate | PT | C0033774 |
| Rash | salicylate | LLT | C0015230 |
| Rash | salicylate | PT | C0015230 |
| Skin exfoliation | salicylate | PT | C0237849 |
| Skin papilloma | salicylate | PT | C0347390 |
| Somnolence | salicylate | PT | C2830004 |
| Stinging | salicylate | LLT | C0677500 |
| Tinnitus | salicylate | LLT | C0040264 |
| Tinnitus | salicylate | PT | C0040264 |
| Upset stomach | salicylate | LLT | C0235309 |
| Urticaria | salicylate | LLT | C0042109 |
| Urticaria | salicylate | PT | C0042109 |
| Vomiting | salicylate | LLT | C0042963 |
| Vomiting | salicylate | PT | C0042963 |
| Warts | salicylate | LLT | C3665596 |
| Weight increased | salicylate | LLT | C0043094 |
| Weight increased | salicylate | PT | C0043094 |
SOURCE
Rendered pharma page rows
FAQPage JSON-LD
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Salicylic Acid used for in pharmaceutical contexts?
Salicylic Acid (CAS 69-72-7) appears in DailyMed active-ingredient label rows, including AOAO Acne Buster Salicylic Acid Drying Serum, Antispetic, Follence Medicated.
What are the known adverse events for Salicylic Acid?
Salicylic Acid has 2,019 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Macular degeneration, Completed suicide, Chronic sinusitis, Toxicity to various agents, Paraesthesia oral. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Salicylic Acid also used in cosmetics?
No same-CAS cosmetics profile is rendered from the ingredients-table cross-reference for Salicylic Acid.
What clinical phase is Salicylic Acid in?
Salicylic Acid is rendered with ChEMBL max phase 3.
What bioactivity targets are documented for Salicylic Acid?
Salicylic Acid has 21 bioactivity rows in this page query. Rendered target entries include Carbonic anhydrase 2, Carbonic anhydrase 1, Carbonic anhydrase 4, Salicylic acid-binding protein 2, Carbonic anhydrase 9.